Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to share their medical information and health data for this study
- People who have been diagnosed with a type of lung cancer called ALK-positive non-small cell lung cancer
- People who are 18 years of age or older
- People who have already received treatment with a medicine called Iruplinalkib
Who may not be able to join:
- People who are known to be pregnant or breastfeeding
- People who have certain lung conditions — such as interstitial lung disease, lung inflammation caused by medication, or lung inflammation caused by radiation — that currently require ongoing medical treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: JinMing Yu, PhD, Shandong Cancer Hospital and Institute
Phone: 8613806406293
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.